Targeting the JNK-JUN pathway to reduce phenotypic plasticity and overcome therapy resistance in metastatic melanoma

Petranel Ferrao

Institute for Breathing and Sleep

Dr Ferrao has over 15 years of research, teaching and commercial experience in the biomedical sciences. With a passion for translational research she has led innovative research to novel discoveries that have contributed to the advancement of cancer treatments in clinical development. Building upon her training and expertise in Receptor Tyrosine kinases, signalling and drug resistance, she focuses on two main areas: defining predictors of therapy response and investigating mechanisms of drug resistance to cancer treatments. She has a clear vision for contributing to precision medicine through innovative research by advancing the personalised use of current/new therapies for patient benefit.


IntroductionPatients with metastatic melanoma have displayed remarkable responses to targeted and immune therapies that have been approved for treatment in recent years. However, responses to targeted therapies are partial or... [ view full abstract ]


  1. Petranel Ferrao (Institute for Breathing and Sleep)

Topic Area

Drug target discovery and integration with individualized therapy, integration of diagnosi


PS1 » Poster Session (14:00 - Monday, 25th June, Main hall)

Presentation Files

The presenter has not uploaded any presentation files.